Cancer Immunology & Immunotherapy 2008: From Discovery to Development to Drug

Newswise — On September 15-17, 2008, the Cancer Research Institute will host a joint meeting of the XVIth CRI International Cancer Immunotherapy Symposium and 2008 CRI Cancer Vaccine Consortium Colloquium. The title of this year's meeting is Cancer Immunology and Immunotherapy 2008: From Discovery to Development to Drug, and it will be divided into the following sessions:

I: Cancer Immunoediting and Cancer and InflammationII: Immunological Consequences of Current Cancer TherapyIII: Cross Presentation and Tumor StromaIV: Modulators of Immune Escape MechanismsV: Adoptive ImmunotherapyVI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials

The meeting will consist of a series of 27 plenary lectures by prominent immunologists and tumor immunologists and a poster session featuring 100 presentations from scientists around the world.

Speakers at the meeting include:

James P. Allison, Ph.D.Ludwig Center for Cancer Immunotherapy,Howard Hughes Medical InstituteMemorial Sloan-Kettering Cancer Center, New York, NY

David Berman, M.D., Ph.D.Bristol-Myers Squibb, Princeton, NJ

Michael J. Bevan, Ph.D.University of Washington School of Medicine, Seattle, WA

Vincenzo Bronte, M.D.Istituto Oncologico Veneto and Venetian Institute for Molecular Medicine, Padova, Italy

George Coukos, M.D., Ph.D.University of Pennsylvania Medical Center, Philadelphia, PA

Glenn Dranoff, M.D.Dana-Farber Cancer Institute, Boston, MA

Wolf H. Fridman, M.D., Ph.D.University Paris Descartes and University Pierre et Marie Curie, Paris, France

Sacha Gnjatic, Ph.D.Ludwig Institute for Cancer Research,Memorial Sloan-Kettering Cancer Center, New York, NY

Cécile Gouttefangeas, Ph.D.University of Tübingen, Tübingen, Germany

Günter J. HämmerlingGerman Cancer Research Center, DKFZ Heidelberg, Heidelberg, Germany

Adrian Hayday, MA, Ph.D.King's College School of Medicine at Guy's Hospital, London, UK

Kristen M. Hege, M.D.Cell Genesys, Inc., South San Francisco, CA

Frederic LehmannGlaxoSmithKline Biologicals, Rixensart, Belgium

Hyam Levitsky, M.D.John Hopkins University School of Medicine, Baltimore, MD

Ellen Puré, Ph.D.The Wistar Institute, Philadelphia, PA, andThe Ludwig Institute for Cancer Research, New York, NY

Jeffrey V. Ravetch, M.D., Ph.D.The Rockefeller University, New York, NY

Michel Sadelain, M.D., Ph.D.Memorial Sloan-Kettering Cancer Center, New York, NY

Robert D. Schreiber, Ph.D.Washington University School of Medicine, St. Louis, MO

Padmanee Sharma, M.D., Ph.D.The University of Texas M.D. Anderson Cancer Center, Houston, TX

Arlene Sharpe, M.D., Ph.D. Harvard Medical School & Brigham and Women's Hospital, Boston, MA

Michail V. Sitkovsky, Ph.D.N.E. Inflammation and Tissue Protection Institute, Northeastern University, Boston, MA

Mark J. Smyth, Ph.D.Peter MacCallum Cancer Centre, Victoria, Australia

Pramod K. Srivastava, Ph.D.Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT

Jedd D. Wolchok, M.D., Ph.D.Memorial Sloan-Kettering Cancer Center, New York, NY

Cassian Yee, M.D.Fred Hutchinson Cancer Research Center & University of Washington, Seattle, WA

Laurence Zitvogel, Ph.D.Institut GustaveRoussy, Villejuif, France

A complete agenda and list of speakers for the meeting may be found on the Cancer Research Institute website, http://www.cancerresearch.org/events/symposium/cancer-immunology-immunotherapy-2008/index.html.Credentialed members of the press are strongly encouraged to attend this timely conference.

About the Cancer Research InstituteThe Cancer Research Institute (CRI) is the world's only non-profit, private organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes five Nobel Prize winners and twenty-nine members of the National Academy of Sciences, CRI supports the finest cutting-edge cancer research at top medical centers and universities throughout the world. As the initiator and steward of unprecedented global laboratory and clinical programs like the Cancer Vaccine Collaborative, a partnership with the Ludwig Institute for Cancer Research, and the Coordinated Cancer Initiatives, the Cancer Research Institute is ushering in a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to cancer patients.

The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. This has consistently earned CRI an A grade or higher for fiscal disclosure and efficiency from the American Institute of Philanthropy, a 4-star rating from Charity Navigator, and top marks from other charity watchdog organizations. http://www.cancerresearch.org.